Common Stock
- Symbol
- CRVO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 8.01, 9.01 · 8-K
CervoMed Inc.
CRVONASDAQEQUITYCurrent
Regulation FD Disclosure · Other Events
Item 7.01 Regulation FD Disclosure On July 9, 2026, CervoMed Inc. (the “Company”) issued a press release announcing it has completed enrollment in the Company’s Phase 2a study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia, a type of frontotemporal dementia (“FTD”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.…
Registered securities in this filing
CervoMed Inc. · 8-K · Filed 2026-07-09
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01
Regulation FD Disclosure
On July 9, 2026, CervoMed Inc. (the “Company”) issued a press release announcing it has completed enrollment in the Company’s Phase 2a study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia, a type of frontotemporal dementia (“FTD”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 8.01Item 8.01 - Other Events
Item 8.01
The information set forth in the first and third paragraphs of, and under the headings “Recent Nature Neuroscience publication supports inhibition of p38α as potential therapeutic approach in FTD,” and “Interim results from the Phase 2a clinical trial to be presented at CTAD” in, the Company’s press release issued on July 9, 2026, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.